Harmony Biosciences 3Q 2026: Revenue $268.92M, Net income $48.2M, EPS $0.81— 10-Q Summary
Harmony Biosciences reported Q3 2026 revenue of $268.92M, up 12.3% YoY, but net income fell 5.2% to $48.2M and EPS declined 6.9% to $0.81. WAKIX revenue grew 12.3% in the quarter, driven by higher shipments and a price increase. The FDA accepted the Pitolisant GR NDA for review, with a target PDUFA date of April 1, 2027. Phase 3 trials for EPX-100 and Pitolisant HD are ongoing, with results expected in 2027. The company also began a Phase 1b study of BP-205.
How this was made
The 30-second read
Why it matters
The mixed earnings result may trigger a modest sell‑off in after‑hours trading, though pipeline progress could sustain longer‑term interest.
Market read
Earnings release provides fresh data for traders; the combination of revenue growth and profit decline creates a nuanced trade signal.
What to watch
Upcoming FDA acceptance of Pitolisant NDA and Phase 3 trial timelines may offset short‑term earnings weakness.
Background
Harmony Biosciences Holdings released its Q3 2026 earnings via a 10‑Q filing, highlighting revenue growth, a decline in net income, and ongoing clinical programs.
Ticker impact
Q3 2026 revenue $268.92M, net income $48.2M, EPS $0.81 reported for the first time.
modest downside as market prices in lower net income and EPS
Revenue rose 12.3% YoY, but net income fell 5.2% and EPS fell 6.9%, a mixed result that typically drags the stock.
Market effects
Biotech sector may see slight pressure as earnings miss expectations despite revenue growth.
U.S. biotech stocks could experience modest pullback in after‑hours trading.
Limited to investors focused on small‑cap biotech earnings.
Counterpoint
Revenue acceleration could signal longer‑term growth, making the stock a buy on dip.
Key entities
- companyHarmony Biosciences Holdings
U.S. biotech firm reporting Q3 2026 results.